The community gives you the chance to connect and engage with delegates attending this event.

Access to the community is available for registered attendees only.

If you have already registered, please join using the link below. To register for the event please follow the 'Register for free' button and summit your details. Please contact ftlive@ft.com with any questions.

Biopharma Manufacturing for Advanced Therapies

Improving processes to optimise efficiencies and increase patient access

On-demand video now available

Presented by

In Partnership with

New medicines show enormous promise, but a number of important challenges will need to be addressed

This Financial Times event, organised in partnership with Cytiva, brought together pharma, biotech, CDMOs, industry suppliers of services and equipment, and other players engaged in the fast-growing field of RNA, Cell and Gene, ATMPs manufacture and commercialisation. The focus was on innovative ways to expedite and improve biomanufacturing and ensure the next generation of advanced therapies can reach patients affordably and at scale.

See full overview

Key Takeaways

Challenges

Biopharma manufacturing faces challenges in scaling, personalising and speed/agility for advanced therapies.

Scalability

Building a scalable ecosystem is crucial for industrialising production and bringing therapies to market.

Automation and Flexibility

Finding the right balance between automation and flexibility is key to addressing scalability and cost challenges.

World-Class Business Leaders and Speakers

Jerh Collins

Chief Technical Operations and Quality Officer

Moderna

Daniel Palmacci

President of Cell & Gene

Lonza

Charlene Banard

EVP & Chief Technical Officer

Atara Biotherapeutics

Scott Ripley

General Manager, Nucleic Acid Therapeutics

Cytiva

Hannah Kuchler

Global Pharmaceuticals Correspondent

Financial Times

Past Lessons

Past experiences of scaling up can be applied to speed molecules to market.

Collaboration

Collaboration is key to success and having skilled people is essential to keep up with science.

Regulation

Dialogue with regulators is important for the development of advanced therapies and the industry must help regulators become comfortable with them.

See the agenda

Watch now on-demand

FT Live Digital Dialogues - fully digital 50 minute event experiences delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.